Evidence map›Paper›PMID 35346091›Full record

ArticleBMC neurology2022

Genotype-Phenotype correlations of SCARB2 associated clinical presentation: a case report and in-depth literature review.

Burcu Atasu, Ayse Nur Ozdag Acarlı, Basar Bilgic, Betül Baykan, Erol Demir, Yasemin Ozluk, Aydin Turkmen, Ann-Kathrin Hauser, Gamze Guven, Hasmet Hanagasi and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Burcu Atasu *Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. brcdursun@hotmail.com.ORCID http://orcid.org/0000-0002-7662-5803
Ayse Nur Ozdag Acarlı *Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Basar BilgicDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Betül BaykanDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Erol DemirDivision of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Yasemin OzlukDepartment of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Aydin TurkmenDivision of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Ann-Kathrin HauserHertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Gamze GuvenInstitute for Experimental Medicine, Genetics Department, Istanbul University, Istanbul, Turkey.
Hasmet HanagasiDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Hakan GurvitDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Murat EmreDepartment of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Thomas GasserHertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Ebba LohmannHertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Istanbul University · TRGerman Center for Neurodegenerative Diseases · DEKoç University · TR

Funding

Deutsche Forschungsgemeinschaft GA 402/23-1 | LO 2046/2-1
6 · The paper itself

Abstract

backgroundBiallelic pathogenic variants in the SCARB2 gene have been associated with action myoclonus-renal failure (AMRF) syndrome. Even though SCARB2 associated phenotype has been reported to include typical neurological characteristics, depending on the localization and the feature of the pathogenic variants, clinical course and the presentations have been shown to differ. CASE PRESENTATION: Whole exome sequencing (WES) analysis revealed a homozygous truncating variant (p.N45MfsX88) in SCARB2 gene in the index case, and subsequent sanger sequencing analysis validated the variant in all affected family members from a Turkish family with the clinical characteristics associated with AMRF and related disorders. Intrafamilial clinical heterogeneity with common features including dysarthria, tremor and proteinuria, and distinct features such as peripheral neuropathy (PNP), myoclonus and seizures between the affected cases, was observed in the family. In-depth literature review enabled the detailed investigation of the reported variants associated with AMRF and suggested that while the type of the variant did not have a major impact on the course of the clinical characteristics, only the C terminal localization of the pathogenic variant significantly affected the clinical presentation, particularly the age at onset (AO) of the disease.

conclusionsIn this study we showed that biallelic SCARB2 pathogenic variants might cause a spectrum of common and distinct features associated with AMRF. Of those features while the common features include myoclonus (100%), ataxia (96%), tonic clonic seizures (82%), dysarthria (68%), tremor (65%), and renal impairment (62%), the uncommon features involve PNP (17%), hearing loss (6.8%), and cognitive impairment (13.7%). AO has been found to be significantly higher in the carriers of the p.G462DfsX34 pathogenic variant. SCARB2 pathogenic variants have not been only implicated in AMRF but also in the pathogenesis of Parkinson's disease (PD) and Gaucher disease (GD), suggesting the importance of genetic and functional studies in the clinical and the diagnostic settings. Given the proven role of SCARB2 gene in the pathogenesis of AMRF, PD and GD with a wide spectrum of clinical symptoms, investigation of the possible modifiers, such as progranulin and HSP7, has a great importance.

Indexed as

Myoclonic Epilepsies, ProgressiveGenetic Association StudiesHumansLysosomal Membrane ProteinsPhenotypeReceptors, ScavengerLysosomal Membrane ProteinsReceptors, ScavengerAction Myoclonus-Renal Failure SyndromeAtaxiaGaucher diseaseParkinson’s diseasePathogenic variantsProgressive Myoclonic EpilepsySCARB2

Identifiers

PMID35346091
PMCPMC8962058
OpenAlexW4220686924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.